CD274 and non-small cell lung carcinoma: Because of its relevance in triggering cancer-related tolerance in NSCLC and for its targetability in immunotherapy with immune-checkpoint inhibitors, which NSCLC is particularly responsive to [37], we chose to also investigate the immunohistochemical expression of the immune-checkpoint molecule PD-L1.